Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]

Group 1 - In the first four months of the year, 555 out of 999 comparable ordinary stock funds achieved positive performance, accounting for 55% of the total, with 25 funds rising over 20% [1] - The top-performing funds include Ping An Advanced Manufacturing Theme Stock A and C, with returns of 52.59% and 52.29% respectively [1] - The top ten holdings of the Ping An Advanced Manufacturing fund include Hengli Hydraulic, Zhejiang Rongtai, and Huashu High-Tech [1] Group 2 - The healthcare sector saw significant gains, with funds like Bank of China Health A and C, and Huaan Pharmaceutical Biotech A and C achieving returns of 41.72%, 41.53%, 40.70%, and 40.52% respectively [2] - The top holdings of the Bank of China Health fund include Heng Rui Medicine and Xin Nuo Wei [2] - The management of the Bank of China Health fund transitioned to Wang Fangzhou and Zheng Ning in March [2] Group 3 - The worst-performing fund was Guolian An Technology Power Stock, which declined by 17.45% [3] - This fund's top holdings include Hengxuan Technology and Ruixin Micro [3] - The fund is managed by veteran Pan Ming, who has extensive experience in investment management [3] Group 4 - Several funds, including Caitong Integrated Circuit Industry Stock C and GF High-end Manufacturing Stock C, suffered declines of 15.02% to 14.70% due to poor performance in the technology and new energy sectors [4] - The performance of these funds reflects broader challenges in the technology and manufacturing sectors [4] Group 5 - The top 100 stock funds by performance in the first four months show a diverse range of returns, with Ping An Advanced Manufacturing leading and several healthcare funds also performing well [5][6] - The data indicates a strong interest in healthcare and advanced manufacturing sectors among investors [5][6]